Position in DTIL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$105,110
New position
Shares Held
19,111
first reported quarter
Ownership
0.074%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#44
of 78 holders
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 99.28836795562765.ToString("F0")%
Shared 0.ToString("F0")%
None 0.711632044372351.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Focus Partners Wealth holds $172,241,737 across 69 Biotechnology names. DTIL ranks #40 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
131,435 | $58,690,984 | |
| 2 | CELC |
Celcuity Inc.
|
233,390 | $26,639,134 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
16,441 | $12,702,974 | |
| 4 | IONS |
Ionis Pharmaceuticals Inc
|
165,544 | $12,430,698 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
169,286 | $10,940,954 | |
| 6 | INCY |
Incyte Corp
|
116,075 | $10,924,979 | |
| 7 | RPRX |
Royalty Pharma plc
|
116,250 | $5,576,512 | |
| 8 | EXEL |
Exelixis, Inc.
|
107,776 | $4,622,512 |
All Filings in DTIL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $105,110 | 19,111 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||